E. Ohman J:or Asset Management’s AstraZeneca AZN Stock Holding History

E. Ohman J:or Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	-$66	–	421
2022 Q1	$66	Hold	1	–	–	﹤0.01%	425
2021 Q4	$58	Hold	1	–	–	﹤0.01%	432
2021 Q3	$60	Buy	+1	New	+$116	﹤0.01%	460

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

E. Ohman J:or Asset Management's AZN Position: Q2 2022 in Review

E. Ohman J:or Asset Management sold out of AstraZeneca (AZN) in Q2 2022, closing a stake of 1 share — an estimated $66 sold.

E. Ohman J:or Asset Management first reported a position in AZN in Q3 2021 and held it in 3 quarters. The position peaked at $66 in Q1 2022. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

E. Ohman J:or Asset Management reported no remaining AstraZeneca position as of Q2 2022 after selling out during the quarter.
E. Ohman J:or Asset Management sold 1 AstraZeneca share in Q2 2022, an estimated $66.
E. Ohman J:or Asset Management first reported a position in AstraZeneca in Q3 2021 and held it in 3 quarters.
E. Ohman J:or Asset Management's AstraZeneca position peaked at $66 in Q1 2022.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on E. Ohman J:or Asset Management's 13F filing for Q2 2022, filed 5 Apr 2024.